A Phase 2 interventional study of BMS-945429 Placebo and BMS-945429 in Rheumatoid Arthritis, sponsored by CSL Behring. Completed at 100 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by CSL Behring (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 153 studies in Arthritis, Rheumatoid with a site in Japan — 9 open to participants now, 12 under way, 2 of them phase 3. Arthritis, Rheumatoid · Japan.
Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, this one is the 41st largest by enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2011, is one of 36 in phase 2, and was the 56th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 153 studies in Arthritis, Rheumatoid with a site in Japan are open now. Recruiting first, the newest first:
AbbVie · Sites in Japan, United States
Ages 18–75
Merck Sharp & Dohme LLC · Sites in Japan, Australia, Belgium and 8 more countries
Ages 18–75
GlaxoSmithKline · Sites in Japan, Argentina, Brazil and 6 more countries
Ages 18–70
Eli Lilly and Company · Sites in Japan, Australia, China
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in Japan, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
153 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 43 · Phase 3 69 · Phase 4 10
First in 2003; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 265 across the 132 interventional studies, 505 across the 21 observational. Of the 131 that completed or were terminated, 92 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 153 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Japan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05966519Zimmer BiometROSA Knee Intraoperative Planning Flexibility Study | 2027-01 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07276581AstraZenecaA Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 153 studies in Arthritis, Rheumatoid with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effective dose of BMS-945429 in subjects with inadequate response to Methotrexate in the treatment of moderate to severe Rheumatoid Arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
Drug: BMS-945429 Placebo · Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo
BMS-945429 + Methotrexate + Adalimumab Placebo
Biological: BMS-945429 · Drug: Methotrexate · Drug: Adalimumab Placebo
BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
Biological: BMS-945429 · Drug: Methotrexate Placebo · Drug: Methotrexate · Drug: Adalimumab Placebo
BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
Biological: BMS-945429 · Drug: Methotrexate Placebo · Drug: Methotrexate · Drug: Adalimumab Placebo
Adalimumab + Methotrexate
Drug: Methotrexate · Drug: Adalimumab
Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
Tablets, Oral, 15 mg, Weekly, 48 weeks
Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At 12 Weeks
Percent of Participants With ACR 20 Response
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At 24 weeks
Percent of Participants Achieving ACR 50 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At weeks 12 and 24
Percent of Participants Achieving ACR 70 Response Rate
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
Time frame: At weeks 12 and 24
Mean Change From Baseline in Disease Activity as Measured by Disease Activity Score 28 C-reactive Protein (DAS28-CRP)
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by DAS28-CRP
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
Time frame: At weeks 12 and 24
Mean Change From Baseline in Clinical Disease Activity Index (CDAI)
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by CDAI
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
Time frame: At weeks 12 and 24
Mean Change From Baseline in Simplified Disease Activity Index (SDAI)
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
Time frame: Baseline, weeks 12 and 24
Percent of Participants With Remission by SDAI
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
Time frame: At weeks 12 and 24
Percent of Participants With Remission Rate by Boolean Definition
Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)
Time frame: At weeks 12 and 24
Mean Change From Baseline in Health Assessment Questionnaire (HAQ) Disability Index
Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Short Form 36 (SF-36) as Measured by Physical and Mental Components
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Fatigue Severity (VAS) Score
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Scores
The WPAI yeilds four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivty loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.
Time frame: Baseline, weeks 12 and 24
Mean Change From Baseline in Radiographic (MRI) Progression of Synovitis, Osteitis (Bone Marrow Edema), Bone Erosion and Cartilage Loss (Joint-space Narrowing)
Time frame: Baseline and week 12
Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score
The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is \> 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.
Time frame: Baseline and week 24
| Milestone | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Started | 61 | 59 | 60 | 60 | 59 | 60 | 59 |
| Completed | 56 | 59 | 56 | 59 | 54 | 56 | 59 |
| Not completed | 5 | 0 | 4 | 1 | 5 | 4 | 0 |
| Withdrew: Lack of efficacy | 3 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 4 | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 3 | 1 | 0 | 1 | 0 |
| Milestone | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Started | 56 | 58 | 56 | 59 | 54 | 55 | 59 |
| Completed | 47 | 57 | 52 | 54 | 52 | 55 | 54 |
| Not completed | 9 | 1 | 4 | 5 | 2 | 0 | 5 |
| Withdrew: Lack of efficacy | 9 | 0 | 0 | 1 | 2 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 3 | 3 | 0 | 0 | 1 |
| Withdrew: Subject request to discontinue | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Percent of Participants Achieving an American College of Rheumatology (ACR) 20% Response Rate | 39.3 | 76.3 | 55.0 | 73.3 | 61.0 | 60.0 | 76.3 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Percent of Participants With ACR 20 Response | 37.7 | 81.4 | 58.3 | 65.0 | 57.6 | 66.7 | 66.1 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| 12 weeks | 21.3 | 49.2 | 26.7 | 43.3 | 28.8 | 26.7 | 30.5 |
| 24 weeks | 16.4 | 47.5 | 36.7 | 46.7 | 33.9 | 43.3 | 47.5 |
The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure \[most often Health Assessment Questionnaire (HAQ)\], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| 12 weeks | 8.2 | 18.6 | 13.3 | 26.7 | 11.9 | 13.3 | 11.9 |
| 24 weeks | 6.6 | 27.1 | 16.7 | 40.0 | 25.4 | 30.0 | 18.6 |
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| 12 weeks | -1.15 ± 0.1652 | -2.65 ± 0.1610 | -2.29 ± 0.1603 | -2.68 ± 0.1597 | -2.34 ± 0.1665 | -2.52 ± 0.1610 | -2.04 ± 0.1647 |
| 24 weeks | -1.69 ± 0.1825 | -3.01 ± 0.1684 | -2.60 ± 0.1719 | -3.06 ± 0.1713 | -2.55 ± 0.1769 | -2.95 ± 0.1706 | -2.52 ± 0.1769 |
DAS28-CRP = Disease Activity Scores 28 based on C Reactive Protein. A DAS28-CRP below 2.6 is interpreted as remission.
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | 1.6 | 35.6 | 21.7 | 35.0 | 25.4 | 26.7 | 20.3 |
| week 24 | 11.5 | 49.2 | 25.0 | 40.0 | 35.6 | 41.7 | 23.7 |
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | -14.5 ± 1.727 | -22.7 ± 1.686 | -17.7 ± 1.687 | -23.1 ± 1.701 | -19.8 ± 1.738 | -21.0 ± 1.697 | -22.4 ± 1.702 |
| week 24 | -20.3 ± 1.703 | -26.1 ± 1.587 | -22.0 ± 1.613 | -26.9 ± 1.622 | -21.7 ± 1.643 | -25.6 ± 1.606 | -26.2 ± 1.631 |
CDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (SCJ) (0-28) and tender joint count (TJC) (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity. The CDAI has a range from 0 to 76. CDAI \<= 2.8 = Remission CDAI \> 2.8 and \<= 10 = Low Disease Activity CDAI \> 10 and \<= 22 = Moderate Disease Activity CDAI \> 22 = High Disease Activity
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | 3.3 | 11.9 | 8.3 | 8.3 | 3.4 | 3.3 | 8.5 |
| week 24 | 1.6 | 15.3 | 6.7 | 21.7 | 6.8 | 20.0 | 8.5 |
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | -14.5 ± 1.794 | -24.9 ± 1.749 | -20.4 ± 1.745 | -25.3 ± 1.734 | -22.2 ± 1.811 | -23.3 ± 1.747 | -23.2 ± 1.785 |
| week 24 | -20.6 ± 1.812 | -28.4 ± 1.670 | -24.5 ± 1.704 | -29.1 ± 1.698 | -23.5 ± 1.755 | -27.6 ± 1.691 | -27.6 ± 1.752 |
SDAI is a composite index for assessing disease activity. CDAI is based on the simple summation of the count of swollen joint count (0-28) and tender joint count (0-28) along with patient global assessment (0-10) Scale and physician global assessment (0-10) for estimating disease activity where 10 means maximal activity and C-reactive protein (0-10). The SDAI has a range from 0 to 86. 0.0 - 3.3 = Remission 3.4 - 11.0 = Low Activity 11.1 - 26.0 = Moderate Activity 26.1 - 86.0 = High Activity
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | 1.6 | 11.9 | 8.3 | 8.3 | 6.8 | 5.0 | 10.2 |
| week 24 | 4.9 | 18.6 | 6.7 | 20. | 6.8 | 23.3 | 8.5 |
Boolean-based definition: At any time point, a patient must satisfy all of the following: TJC ≤1 (0-28) SJC ≤1 (0-28) CRP ≤1 mg/dl Patient Global Assessment ≤1 (on a 0-10 scale)
| percentage of participants | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | 3.3 | 8.5 | 6.7 | 10. | 1.7 | 5.0 | 5.1 |
| week 24 | 1.6 | 10.2 | 5.0 | 13.3 | 5.1 | 18.3 | 10.2 |
Patients report the amount of difficulty they have in performing 8 categories. Each category is scored on a scale ranging from 0 (performed without any difficulty) to 3 (cannot be done at all). The HAQ-DI is then calculated by summing the scores and dividing by the number of categories answered. Total score is between 0-3.0. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment. The HAQ-DI cannot be calculated if the subject does not have scores for at least 6 categories. A response was defined as a subject with a reduction from baseline in HAQ-DI of at least 0.22.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | -0.44 ± 0.0827 | -0.66 ± 0.0801 | -0.47 ± 0.0807 | -0.70 ± 0.0811 | -0.51 ± 0.0834 | -0.60 ± 0.0807 | -0.60 ± 0.0819 |
| week 24 | -0.62 ± 0.0861 | -0.68 ± 0.0806 | -0.64 ± 0.0823 | -0.79 ± 0.0823 | -0.60 ± 0.0840 | -0.71 ± 0.0811 | -0.66 ± 0.0833 |
The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Mental component (week 12) | 5.3 ± 1.274 | 5.9 ± 1.240 | 4.5 ± 1.251 | 7.3 ± 1.244 | 4.0 ± 1.283 | 5.7 ± 1.230 | 6.4 ± 1.250 |
| Mental component (week 24) | 6.0 ± 1.327 | 6.4 ± 1.208 | 6.6 ± 1.247 | 7.5 ± 1.247 | 5.3 ± 1.271 | 8.0 ± 1.219 | 7.1 ± 1.246 |
| Physical component (week 12) | 4.0 ± 1.030 | 7.5 ± 0.999 | 7.3 ± 1.010 | 9.5 ± 1.002 | 6.8 ± 1.028 | 7.3 ± 0.994 | 8.4 ± 1.006 |
| Physical component (week 24) | 6.2 ± 1.149 | 8.6 ± 1.045 | 9.4 ± 1.080 | 10.9 ± 1.076 | 7.7 ± 1.094 | 8.2 ± 1.057 | 8.2 ± 1.077 |
A 9-item questionnaire with questions related to how fatigue interferes with certain activities and rates its severity according to a self-report scale. The items are scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | -14.3 ± 3.146 | -20.8 ± 3.060 | -19.4 ± 3.077 | -27.4 ± 3.077 | -21.7 ± 3.180 | -18.6 ± 3.056 | -26.3 ± 3.080 |
| week 24 | -12.9 ± 3.306 | -23.9 ± 3.052 | -22.3 ± 3.131 | -31.3 ± 3.103 | -17.7 ± 3.184 | -23.4 ± 3.056 | -27.0 ± 3.134 |
The WPAI yeilds four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivty loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment WPAI outcomes are expressed as impairment percentages with each subscale score ranging from 0-100. The subscale scores are added and averaged to produce a total WPAI score between 0-100. Higher scores indicate greater impairment and less productivity.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| week 12 | -9.6 ± 3.273 | -2.2 ± 3.443 | -8.7 ± 3.673 | -12.0 ± 3.081 | -13.7 ± 3.285 | -10.0 ± 3.575 | -11.7 ± 6.281 |
| week 24 | -10.7 ± 4.033 | -1.8 ± 3.893 | -17.1 ± 4.200 | -12.1 ± 3.448 | -5.9 ± 3.788 | -12.6 ± 3.938 | -4.7 ± 6.379 |
| cubic millimeters | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Erosion | 1.3 ± 0.352 | 0.4 ± 0.341 | 1.1 ± 0.356 | 0.3 ± 0.334 | 1.0 ± 0.369 | -0.2 ± 0.341 | -0.5 ± 0.348 |
| Edema | 0.2 ± 1.009 | -6.4 ± 0.993 | -2.6 ± 1.015 | -4.7 ± 0.998 | -4.6 ± 1.036 | -5.1 ± 0.993 | -3.1 ± 1.008 |
| Synovitis | -0.5 ± 0.436 | -2.5 ± 0.427 | -1.4 ± 0.440 | -2.2 ± 0.426 | -2.9 ± 0.447 | -2.5 ± 0.427 | -2.9 ± 0.435 |
| Narrowing | 0.1 ± 0.133 | -0.1 ± 0.130 | 0.2 ± 0.135 | -0.1 ± 0.126 | 0.1 ± 0.139 | 0.0 ± 0.129 | -0.2 ± 0.132 |
The Sharp-van der Heijde total score ranges from 0-528. Scores for erosion range from 0 to 5 in the hands and 0 to 10 in the feet and reflect erosion size, with 0 defined as no erosion and 3 defined as a large erosion passing the midline of the joint. If there is \> 1 erosion per joint, scores can be combined to give a maximum score of 5 per joint in the hands and 10 per joint in the feet (a maximum of 5 at each side of the joint). Joint space narrowing scores vary from 0 to 4 in both the hands and feet, with 0 being normal and 4 being the absence of joint space with evident ankylosis or subluxation. Gross osteolysis and pencil-in-cup change are scored separately and, if present, are assigned the maximum score for erosion and joint space narrowing for the same affected joint. Higher scores indicate increased joint damage.
| score on a scale | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Mean Change From Baseline in Radiographic (X-ray) Progression of Joint Damage as Measured by Modified Sharp/Van Der Heijde Total Score | 1.8 ± 0.353 | 0.3 ± 0.320 | 0.0 ± 0.327 | 0.1 ± 0.324 | 0.1 ± 0.330 | 0.1 ± 0.336 | 0.1 ± 0.333 |
Collected over Up to 48 weeks per participant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo+MTX | 0/61 (0%) | 2/61 (3.3%) | 24/61 (39.3%) |
| Clazakizumab(25)+MTX | 0/59 (0%) | 5/59 (8.5%) | 43/59 (72.9%) |
| Clazakizumab(100) | 0/60 (0%) | 5/60 (8.3%) | 43/60 (71.7%) |
| Clazakizumab(100)+MTX | 0/60 (0%) | 5/60 (8.3%) | 51/60 (85%) |
| Clazakizumab(200) | 0/59 (0%) | 8/59 (13.6%) | 43/59 (72.9%) |
| Clazakizumab(200)+MTX | 0/60 (0%) | 5/60 (8.3%) | 50/60 (83.3%) |
| ADA+MTX | 0/59 (0%) | 3/59 (5.1%) | 35/59 (59.3%) |
| Event | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/61 | 1/59 | 0/60 | 0/60 | 3/59 | 0/60 | 0/59 |
| CellulitisInfections and infestations | 0/61 | 2/59 | 0/60 | 0/60 | 0/59 | 0/60 | 0/59 |
| AppendicitisInfections and infestations | 0/61 | 0/59 | 0/60 | 2/60 | 0/59 | 0/60 | 0/59 |
| PneumoniaInfections and infestations | 0/61 | 0/59 | 0/60 | 1/60 | 0/59 | 0/60 | 1/59 |
| Pulmonary tuberculosisInfections and infestations | 0/61 | 0/59 | 0/60 | 1/60 | 1/59 | 0/60 | 0/59 |
| Bursitis infectiveInfections and infestations | 0/61 | 0/59 | 0/60 | 0/60 | 1/59 | 0/60 | 0/59 |
| Herpes zosterInfections and infestations | 0/61 | 0/59 | 0/60 | 0/60 | 0/59 | 0/60 | 1/59 |
| Urinary tract infectionInfections and infestations | 0/61 | 0/59 | 0/60 | 0/60 | 1/59 | 0/60 | 0/59 |
| Foot fractureInjury, poisoning and procedural complications | 0/61 | 1/59 | 0/60 | 0/60 | 0/59 | 0/60 | 0/59 |
| Acute coronary syndromeCardiac disorders | 0/61 | 1/59 | 0/60 | 0/60 | 0/59 | 0/60 | 0/59 |
| Event | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX |
|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 2/61 | 11/59 | 2/60 | 13/60 | 1/59 | 18/60 | 3/59 |
| Ejection site erythemaGeneral disorders | 0/61 | 2/59 | 8/60 | 15/60 | 10/59 | 9/60 | 2/59 |
| Injection site reactionGeneral disorders | 0/61 | 8/59 | 9/60 | 11/60 | 14/59 | 9/60 | 1/59 |
| Aspartate aminotransferase increasedInvestigations | 0/61 | 8/59 | 0/60 | 14/60 | 0/59 | 12/60 | 2/59 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 2/61 | 7/59 | 7/60 | 5/60 | 5/59 | 9/60 | 2/59 |
| Injection site rashGeneral disorders | 0/61 | 1/59 | 8/60 | 8/60 | 2/59 | 8/60 | 0/59 |
| Upper respiraory tract infectionInfections and infestations | 7/61 | 5/59 | 1/60 | 3/60 | 7/59 | 1/60 | 0/59 |
| DyslipidaemiaMetabolism and nutrition disorders | 1/61 | 7/59 | 4/60 | 2/60 | 2/59 | 4/60 | 1/59 |
| Injection site dermatitisGeneral disorders | 0/61 | 4/59 | 3/60 | 4/60 | 4/59 | 7/60 | 0/59 |
| NasopharyngitisInfections and infestations | 4/61 | 2/59 | 3/60 | 4/60 | 3/59 | 7/60 | 2/59 |
| Age, Categorical(Participants) | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 54 | 56 | 47 | 52 | 51 | 55 | 51 | 366 |
| >=65 years | 7 | 3 | 13 | 8 | 8 | 5 | 8 | 52 |
| Age, Continuous(years) | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 51.4 ± 11.03 | 47.4 ± 10.97 | 55.0 ± 12.21 | 49.9 ± 13.95 | 50.0 ± 12.53 | 46.4 ± 11.91 | 52.8 ± 11.41 | 50.4 ± 12.26 |
| Sex: Female, Male(Participants) | Placebo+MTX | Clazakizumab(25)+MTX | Clazakizumab(100) | Clazakizumab(100)+MTX | Clazakizumab(200) | Clazakizumab(200)+MTX | ADA+MTX | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 46 | 46 | 52 | 53 | 49 | 49 | 48 | 343 |
| Male | 15 | 13 | 8 | 7 | 10 | 11 | 11 | 75 |
The record gives a start of Jun 2011, a primary completion of Sep 2012 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2021, 9 years 3 months after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clazakizumab